ArticleVirulence2026
N-linked glycosylation of GETV envelope proteins affect viral infection and pathogenicity.
Article in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Getah virus (GETV) is an emerging mosquito-borne pathogen with a broad host range, posing a significant threat to livestock and public health. Although putative N-linked glycosylation sites on its envelope proteins have been reported, their precise functional roles remain uncharacterized. In this study, tunicamycin inhibition assays demonstrated that GETV replication depends on the host glycosylation machinery. Enzymatic dissection revealed that the envelope proteins E1 and E2 carry complex-type N-linked glycans, which are critical for infectivity. By constructing envelope protein N-linked glycosylation site mutants, it was revealed that the E1-N141 site influences viral entry, whereas the E2-N262 site was critical for both viral adsorption and internalization. Mutations at all envelope protein N-linked glycosylation sites impaired the infectivity of progeny virions, resulting in delayed replication kinetics and significantly reduced viral titers. In ICR mice model, all mutants showed attenuated pathogenicity, with the E2-N200 mutation conferring the most substantial reduction in virulence. Notably, despite reduced virulence, some mutants (E1-N141A and E2-N200A/N262A) elicited neutralizing antibody responses stronger than those induced by wild-type virus and provided complete protection against subsequent challenge with wild-type GETV. These findings highlight the critical role of envelope protein glycosylation in GETV infectivity and pathogenesis, providing a molecular basis for rational vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.